Hydrocortisone: a timeless milestone in clinical therapy
Authors
monica.montopoli@unipd.it
Keywords
Clinical practice, glucocorticoid, hydrocortisone, inflammation, pharmacokineticsAbstract
First isolated in 1949 and introduced into clinical practice in the early 1950s, hydrocortisone revolutionized the treatment of inflammatory and endocrine disorders. Despite the development of more potent and longer-acting glucocorticoids, it remains indispensable in modern medicine.
This review explores hydrocortisone’s enduring relevance by examining its pharmacokinetic properties, therapeutic indications, and versatility across clinical contexts. The favorable safety profile of hydrocortisone and its predictable pharmacokinetics allow its practice for both topical and systemic administration. Topical formulations are widely used for mild to moderate inflammatory skin conditions, while localized injections deliver targeted relief in joint and soft-tissue disorders. Systemic regimens, ranging from physiological replacement to high-dose medication, address endocrine deficiencies, acute crises, and severe inflammatory flares. This review summarizes clinical evidence on the safety and efficacy of hydrocortisone across a broad spectrum of conditions, reinforcing its role as a reliable and versatile glucocorticoid in modern medicine.
References
- Scherholz ML, Schlesinger N, Androulakis IP. Chronopharmacology of Glucocorticoids. Adv Drug Deliv Rev 2019;151–152:245–61. doi: 10.1016/j.addr.2019.02.004.
- Cooney WP. Compound F: The History of Hydrocortisone and Hand Surgery. The Journal of Hand Surgery 2013;38:774–8. doi: 10.1016/j.jhsa.2012.12.025.
- Oakley RH, Cidlowski JA. The biology of the glucocorticoid receptor: New signaling mechanisms in health and disease. Journal of Allergy and Clinical Immunology 2013;132:1033–44. doi: 10.1016/j.jaci.2013.09.007.
- Czock D, Keller F, Rasche FM, Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 2005;44:61–98. doi: 10.2165/00003088-200544010-00003.
- Hench PS, Kendall EC, Slocumb CH, Polley HF. Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions. Arch Intern Med (Chic) 1950;85:545–666. doi: 10.1001/archinte.1950.00230100002001.
- Burns CM. The History of Cortisone Discovery and Development. Rheum Dis Clin North Am 2016;42:1–14, vii. doi: 10.1016/j.rdc.2015.08.001.
- Kendall EC. Cortisone. Ann Intern Med 1950;33:787–96. doi: 10.7326/0003-4819-33-4-787.
- Camp CL, Morrey BF, Trousdale RT. The beginnings of Orthopedic Surgery at the Mayo Clinic: A Review of the First Orthopedic Patients who Presented Over 100 Years Ago. Iowa Orthop J 2016;36:41–5.
- Howard LD, Pratt DR, Bunnell S. The use of compound F (hydrocortone) in operative and non-operative conditions of the hand. J Bone Joint Surg Am 1953;35-A:994–1002.
- Hollander JL. The local effects of compound F (hydrocortisone) injected into joints. Bull Rheum Dis 1951;2:3–4.
- Derendorf H, Möllmann H, Barth J, Möllmann C, Tunn S, Krieg M. Pharmacokinetics and oral bioavailability of hydrocortisone. J Clin Pharmacol 1991;31:473–6. doi: 10.1002/j.1552-4604.1991.tb01906.x.
- Toothaker RD, Welling PG. Effect of dose size on the pharmacokinetics of intravenous hydrocortisone during endogenous hydrocortisone suppression. J Pharmacokinet Biopharm 1982;10:147–56. doi: 10.1007/BF01062332.
- Hamitouche N, Comets E, Ribot M, Alvarez J-C, Bellissant E, Laviolle B. Population Pharmacokinetic-Pharmacodynamic Model of Oral Fludrocortisone and Intravenous Hydrocortisone in Healthy Volunteers. AAPS J 2017;19:727–35. doi: 10.1208/s12248-016-0041-9.
- Derendorf H, Nave R, Drollmann A, Cerasoli F, Wurst W. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. European Respiratory Journal 2006;28:1042–50. doi: 10.1183/09031936.00074905.
- Barnes PJ. Inhaled Corticosteroids. Pharmaceuticals 2010;3:514–40. doi: 10.3390/ph3030514.
- Laurberg G. Topical treatment with urea-hydrocortisone in atopic dermatitis. A controlled study against betamethasone 17-valerate. Dermatologica 1975;151:30–3. doi: 10.1159/000251310.
- Mehta AB, Nadkarni NJ, Patil SP, Godse KV, Gautam M, Agarwal S. Topical corticosteroids in dermatology. Indian J Dermatol Venereol Leprol 2016;82:371–8. doi: 10.4103/0378-6323.178903.
- Aalto-Korte K, Turpeinen M. Pharmacokinetics of topical hydrocortisone at plasma level after applications once or twice daily in patients with widespread dermatitis. Br J Dermatol 1995;133:259–63. doi: 10.1111/j.1365-2133.1995.tb02625.x.
- Turpeinen M, Mashkilleyson N, Björkstén F, Salo OP. Percutaneous absorption of hydrocortisone during exacerbation and remission of atopic dermatitis in adults. Acta Derm Venereol 1988;68:331–5.
- Jones IA, Togashi R, Wilson ML, Heckmann N, Vangsness CT. Intra-articular treatment options for knee osteoarthritis. Nat Rev Rheumatol 2019;15:77–90. doi: 10.1038/s41584-018-0123-4.
- Evans CH, Kraus VB, Setton LA. Progress in intra-articular therapy. Nat Rev Rheumatol 2014;10:11–22. doi: 10.1038/nrrheum.2013.159.
- Swartz SL, Dluhy RG. Corticosteroids: Clinical Pharmacology and Therapeutic Use. Drugs 1978;16:238–55. doi: 10.2165/00003495-197816030-00006.
- Rosman PM, Benn R, Kay M, Tito J, Wallace EZ. Cortisol binding in uremic plasma. I. Absence of abnormal cortisol binding to cortisol binding to corticosteroid-binding globulin. Nephron 1984;37:160–5. doi: 10.1159/000183237.
- Rosman PM, Benn R, Kay M, Wallace EZ. Cortisol binding in uremic plasma. II. Decreased cortisol binding to albumin. Nephron 1984;37:229–31. doi: 10.1159/000183254.
- Lewis JG, Bagley CJ, Elder PA, Bachmann AW, Torpy DJ. Plasma free cortisol fraction reflects levels of functioning corticosteroid-binding globulin. Clinica Chimica Acta 2005;359:189–94. doi: 10.1016/j.cccn.2005.03.044.
- Perogamvros I, Aarons L, Miller AG, Trainer PJ, Ray DW. Corticosteroid-binding globulin regulates cortisol pharmacokinetics. Clinical Endocrinology 2011;74:30–6. doi: 10.1111/j.1365-2265.2010.03897.x.
- Gagliardi L, Ho JT, Torpy DJ. Corticosteroid-binding globulin: the clinical significance of altered levels and heritable mutations. Mol Cell Endocrinol 2010;316:24–34. doi: 10.1016/j.mce.2009.07.015.
- Cameron A, Henley D, Carrell R, Zhou A, Clarke A, Lightman S. Temperature-responsive release of cortisol from its binding globulin: a protein thermocouple. J Clin Endocrinol Metab 2010;95:4689–95. doi: 10.1210/jc.2010-0942.
- Almazroo OA, Miah MK, Venkataramanan R. Drug Metabolism in the Liver. Clinics in Liver Disease 2017;21:1–20. doi: 10.1016/j.cld.2016.08.001.
- Tomlinson JW, Stewart PM. Cortisol metabolism and the role of 11beta-hydroxysteroid dehydrogenase. Best Practice & Research Clinical Endocrinology & Metabolism 2001;15:61–78. doi: 10.1053/beem.2000.0119.
- Abel SM, Maggs JL, Back DJ, Park BK. Cortisol metabolism by human liver in vitro--I. Metabolite identification and inter-individual variability. J Steroid Biochem Mol Biol 1992;43:713–9. doi: 10.1016/0960-0760(92)90297-v.
- Al-Dujaili EAS, Kenyon CJ, Nicol MR, Mason JI. Liquorice and glycyrrhetinic acid increase DHEA and deoxycorticosterone levels in vivo and in vitro by inhibiting adrenal SULT2A1 activity. Molecular and Cellular Endocrinology 2011;336:102–9. doi: 10.1016/j.mce.2010.12.011.
- Girard C, Barbier O, Veilleux G, El-Alfy M, Bélanger A. Human Uridine Diphosphate-Glucuronosyltransferase UGT2B7 Conjugates Mineralocorticoid and Glucocorticoid Metabolites. Endocrinology 2003;144:2659–68. doi: 10.1210/en.2002-0052.
- Weitzman ED, Fukushima D, Nogeire C, Roffwarg H, Gallagher TF, Hellman L. Twenty-four hour pattern of the episodic secretion of cortisol in normal subjects. J Clin Endocrinol Metab 1971;33:14–22. doi: 10.1210/jcem-33-1-14.
- Bashar T, Apu MNH, Mostaid MS, Islam MS, Hasnat A. Pharmacokinetics and Bioavailability Study of a Prednisolone Tablet as a Single Oral Dose in Bangladeshi Healthy Volunteers. Dose-Response 2018;16:1559325818783932. doi: 10.1177/1559325818783932.
- Spoorenberg SMC et al. Pharmacokinetics of oral vs. intravenous dexamethasone in patients hospitalized with community-acquired pneumonia. Br J Clin Pharmacol 2014;78:78–83. doi: 10.1111/bcp.12295.
- Raff H, Auchus RJ, Findling JW, Nieman LK. Urine free cortisol in the diagnosis of Cushing’s syndrome: is it worth doing and, if so, how? J Clin Endocrinol Metab 2015;100:395–7. doi: 10.1210/jc.2014-3766.
- Fenske M. Urinary free cortisol and cortisone excretion in healthy individuals: Influence of water loading. Steroids 2006;71:1014–8. doi: 10.1016/j.steroids.2006.08.004.
- Fenske M. How Much “Urinary Free Cortisol” Is Really Cortisol during Water Diuresis in Healthy Individuals? Clinical Chemistry 2004;50:1102–4. doi: 10.1373/clinchem.2004.032243.
- Lewicka S, Nowicki M, Vecsei P. Effect of sodium restriction on urinary excretion of cortisol and its metabolites in humans. Steroids 1998;63:401–5. doi: 10.1016/S0039-128X(98)00015-4.
- Müssig K, Remer T, Maser-Gluth C. Brief review: Glucocorticoid excretion in obesity. The Journal of Steroid Biochemistry and Molecular Biology 2010;121:589–93. doi: 10.1016/j.jsbmb.2010.01.008.
- Shamim W, Yousufuddin M, Bakhai A, Coats AJS, Honour JW. Gender differences in the urinary excretion rates of cortisol and androgen metabolites. Ann Clin Biochem 2000;37:770–4. doi: 10.1258/0004563001900084.
- Lamb EJ, Noonan KA, Burrin JM. Urine-Free Cortisol Excretion: Evidence of Sex-Dependence. Ann Clin Biochem 1994;31:455–8. doi: 10.1177/000456329403100505.
- Deng J, Chalhoub NE, Sherwin CM, Li C, Brunner HI. Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus. Seminars in Arthritis and Rheumatism 2019;49:251–9. doi: 10.1016/j.semarthrit.2019.03.010.
- Frank F, Ortlund EA, Liu X. Structural insights into glucocorticoid receptor function. Biochemical Society Transactions 2021;49:2333–43. doi: 10.1042/BST20210419.
- Frauman AG. An overview of the adverse reactions to adrenal corticosteroids. Adverse Drug React Toxicol Rev. 1996;15(4):203-6.
- Guillot B. Effets indésirables cutanés des glucocorticoïdes. La Revue de Médecine Interne 2013;34:310–4. doi: 10.1016/j.revmed.2012.12.004.
- Stratakis CA, Mastorakos G, Mitsiades NS, Mitsiades CS, Chrousos GP. Skin Manifestations of Cushing Disease in Children and Adolescents Before and After the Resolution of Hypercortisolemia. Pediatric Dermatology 1998;15:253–8. doi: 10.1046/j.1525-1470.1998.1998015253.x.
- Haapasaari K, Rossi O, Risteli J, Oikarinen A. Effects of long-term inhaled corticosteroids on skin collagen synthesis and thickness in asthmatic patients. European Respiratory Journal 1998;11:139–43. doi: 10.1183/09031936.98.11010139.
- Kuo T, McQueen A, Chen T-C, Wang J-C. Regulation of Glucose Homeostasis by Glucocorticoids. Adv Exp Med Biol 2015;872:99–126. doi: 10.1007/978-1-4939-2895-8_5.
- van Balkom RH, van der Heijden HF, van Herwaarden CL, Dekhuijzen PN. Corticosteroid-induced myopathy of the respiratory muscles. Neth J Med 1994;45:114–22.
- Suresh E, Wimalaratna S. Proximal myopathy: diagnostic approach and initial management. Postgraduate Medical Journal 2013;89:470–7. doi: 10.1136/postgradmedj-2013-131752.
- Stewart PM. Cortisol as a mineralocorticoid in human disease. J Steroid Biochem Mol Biol 1999;69:403–8. doi: 10.1016/s0960-0760(99)00072-2.
- Grünfeld J-P. Glucocorticoids in Blood Pressure Regulation. Hormone Research 2008;34:111–3. doi: 10.1159/000181807.
- Huscher D, Thiele K, Gromnica-Ihle E, Hein G, Demary W, Dreher R, et al. Dose-related patterns of glucocorticoid-induced side effects. Annals of the Rheumatic Diseases 2009;68:1119–24. doi: 10.1136/ard.2008.092163.
- Powell JR. Steroid and hypokalemic myopathy after corticosteroids for ulcerative colitis. Systemic and tropical application. Am J Gastroenterol 1969;52:425–32.
- Zdrojowy-Welna A, Stachowska B, Bolanowski M. Cushing’s disease and bone. Pituitary 2024;27:837–46. doi: 10.1007/s11102-024-01427-7.
- Leszczynska D, Szatko A, Papierska L, Zgliczynski W, Glinicki P. Musculoskeletal complications of Cushing syndrome. Reumatologia 2023;61:271–82. doi: 10.5114/reum/169889.
- Xing Q, Feng J, Zhang X. Glucocorticoids suppressed osteoblast differentiation by decreasing Sema3A expression via the PIK3/Akt pathway. Experimental Cell Research 2021;403:112595. doi: 10.1016/j.yexcr.2021.112595.
- Chen M, Fu W, Xu H, Liu C. Pathogenic mechanisms of glucocorticoid-induced osteoporosis. Cytokine & Growth Factor Reviews 2023;70:54–66. doi: 10.1016/j.cytogfr.2023.03.002.
- Pluskiewicz W, Adamczyk P, Drozdzowska B. Glucocorticoids Increase Fracture Risk and Fracture Prevalence Independently from Bone Mineral Density and Clinical Risk Factors: Results from the Gliwice Osteoporosis (GO) Study. Hormone and Metabolic Research 2022;54:20–4. doi: 10.1055/a-1700-5007.
- Patel PD, Kodati B, Clark AF. Role of Glucocorticoids and Glucocorticoid Receptors in Glaucoma Pathogenesis. Cells 2023;12:2452. doi: 10.3390/cells12202452.
- Hahner S, Ross RJ, Arlt W, Bancos I, Burger-Stritt S, Torpy DJ, et al. Adrenal insufficiency. Nat Rev Dis Primers 2021;7:1–24. doi: 10.1038/s41572-021-00252-7.
- Prete A, Bancos I. Glucocorticoid induced adrenal insufficiency. BMJ 2021;374:n1380. doi: 10.1136/bmj.n1380.
- Allen DB. GROWTH SUPPRESSION BY GLUCOCORTICOID THERAPY. Endocrinology and Metabolism Clinics of North America 1996;25:699–717. doi: 10.1016/S0889-8529(05)70348-0.
- Tsampalieros A, Knoll GA, Molnar AO, Fergusson N, Fergusson DA. Corticosteroid Use and Growth After Pediatric Solid Organ Transplantation: A Systematic Review and Meta-Analysis. Transplantation 2017;101:694–703. doi: 10.1097/TP.0000000000001320.
- Hochberg Z. Mechanisms of Steroid Impairment of Growth. Hormone Research 2004;58:33–8. doi: 10.1159/000064764.
- Simon D. rhGH Treatment in Corticosteroid-Treated Patients. Hormone Research 2007;68:38–45. doi: 10.1159/000100873.
- Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol 2017;17:233–47. doi: 10.1038/nri.2017.1.
- Barbulescu A, Sjölander A, Delcoigne B, Askling J, Frisell T. Glucocorticoid exposure and the risk of serious infections in rheumatoid arthritis: a marginal structural model application. Rheumatology (Oxford) 2023;62:3391–9. doi: 10.1093/rheumatology/kead083.
- Narum S, Westergren T, Klemp M. Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis. BMJ Open 2014;4:e004587. doi: 10.1136/bmjopen-2013-004587.
- Rice JB, White AG, Scarpati LM, Wan G, Nelson WW. Long-term Systemic Corticosteroid Exposure: A Systematic Literature Review. Clinical Therapeutics 2017;39:2216–29. doi: 10.1016/j.clinthera.2017.09.011.
- Butler DC, Berger T, Elmariah S, Kim B, Chisolm S, Kwatra SG, et al. Chronic Pruritus: A Review. JAMA 2024;331:2114–24. doi: 10.1001/jama.2024.4899.
- Boehncke W-H, Schön MP. Psoriasis. The Lancet 2015;386:983–94. doi: 10.1016/S0140-6736(14)61909-7.
- Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician 2017;63:278–85.
- Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. GUIDELINES OF CARE FOR THE MANAGEMENT OF ATOPIC DERMATITIS. J Am Acad Dermatol 2014;71:116–32. doi: 10.1016/j.jaad.2014.03.023.
- Kerschbaumer A, Sepriano A, Bergstra SA, Smolen JS, van der Heijde D, Caporali R, et al. Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases 2023;82:95–106. doi: 10.1136/ard-2022-223365.
- Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care & Research 2021;73:924–39. doi: 10.1002/acr.24596.
- Wasserman AM. Diagnosis and management of rheumatoid arthritis. Am Fam Physician 2011;84:1245–52.
- Østergaard M, Halberg P. Intra-Articular Corticosteroids in Arthritic Disease. BioDrugs 1998;9:95–103. doi: 10.2165/00063030-199809020-00002.
- Wolff ASB, Kucuka I, Oftedal BE. Autoimmune primary adrenal insufficiency -current diagnostic approaches and future perspectives. Front Endocrinol (Lausanne) 2023;14:1285901. doi: 10.3389/fendo.2023.1285901.
- Bornstein SR et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016;101:364–89. doi: 10.1210/jc.2015-1710.
- Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer GD, et al. An Update on Addison’s Disease. Experimental and Clinical Endocrinology & Diabetes 2018;127:165–75. doi: 10.1055/a-0804-2715.
- Mongioì LM, Condorelli RA, Barbagallo F, La Vignera S, Calogero AE. Dual-release hydrocortisone for treatment of adrenal insufficiency: a systematic review. Endocrine 2020;67:507–15. doi: 10.1007/s12020-020-02187-7.
- Guarnotta V, Di Stefano C, Santoro A, Ciresi A, Coppola A, Giordano C. Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency. Endocr Connect 2019;8:853–62. doi: 10.1530/EC-19-0176.
- Woodcock T, Barker P, Daniel S, Fletcher S, Wass JAH, Tomlinson JW, et al. Guidelines for the management of glucocorticoids during the peri-operative period for patients with adrenal insufficiency: Guidelines from the Association of Anaesthetists, the Royal College of Physicians and the Society for Endocrinology UK. Anaesthesia 2020;75:654–63. doi: 10.1111/anae.14963.
- Jung C, Inder WJ. Management of adrenal insufficiency during the stress of medical illness and surgery. Med J Aust 2008;188. doi: 10.5694/j.1326-5377.2008.tb01686.x.
- Lee JH, Torpy DJ. Adrenal insufficiency in pregnancy: Physiology, diagnosis, management and areas for future research. Rev Endocr Metab Disord 2023;24:57–69. doi: 10.1007/s11154-022-09745-6.
- Martin-Grace J, Tomkins M, O’Reilly MW, Sherlock M. Iatrogenic adrenal insufficiency in adults. Nat Rev Endocrinol 2024;20:209–27. doi: 10.1038/s41574-023-00929-x.
- Arlt W. SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Emergency management of acute adrenal insufficiency (adrenal crisis) in adult patients 2016. doi: 10.1530/EC-16-0054.
- Dodd A, Hughes A, Sargant N, Whyte AF, Soar J, Turner PJ. Evidence update for the treatment of anaphylaxis. Resuscitation 2021;163:86–96. doi: 10.1016/j.resuscitation.2021.04.010.
- Alqurashi W, Ellis AK. Do Corticosteroids Prevent Biphasic Anaphylaxis? J Allergy Clin Immunol Pract 2017;5:1194–205. doi: 10.1016/j.jaip.2017.05.022.
- Whyte AF, Soar J, Dodd A, Hughes A, Sargant N, Turner PJ. Emergency treatment of anaphylaxis: concise clinical guidance. Clinical Medicine 2022;22:332–9. doi: 10.7861/clinmed.2022-0073.
- Jeong DY, Kim S, Son MJ, Son CY, Kim JY, Kronbichler A, et al. Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review. Autoimmun Rev 2019;18:439–54. doi: 10.1016/j.autrev.2019.03.002.
- Seyedian SS, Nokhostin F, Malamir MD. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J Med Life 2019;12:113–22. doi: 10.25122/jml-2018-0075.
- Du L, Ha C. Epidemiology and Pathogenesis of Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:643–54. doi: 10.1016/j.gtc.2020.07.005.
- Rivière P, Li Wai Suen C, Chaparro M, De Cruz P, Spinelli A, Laharie D. Acute severe ulcerative colitis management: unanswered questions and latest insights. Lancet Gastroenterol Hepatol 2024;9:251–62. doi: 10.1016/S2468-1253(23)00313-8.
- Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019;68:s1–106. doi: 10.1136/gutjnl-2019-318484.
- Hwang H, Park J, Lee WK, Lee WH, Leigh JH, Lee JJ, et al. Crystallization of Local Anesthetics When Mixed With Corticosteroid Solutions. Ann Rehabil Med 2016;40:21–7. doi: 10.5535/arm.2016.40.1.21.
- Werumeus Buning J, Touw DJ, Brummelman P, Dullaart RPF, van den Berg G, van der Klauw MM, et al. Pharmacokinetics of oral hydrocortisone - Results and implications from a randomized controlled trial. Metabolism 2017;71:7–16. doi: 10.1016/j.metabol.2017.02.005.